F M Investments LLC Decreases Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

F M Investments LLC reduced its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 8.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 56,313 shares of the specialty pharmaceutical company's stock after selling 5,469 shares during the period. F M Investments LLC owned about 0.27% of ANI Pharmaceuticals worth $3,113,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. US Bancorp DE increased its stake in shares of ANI Pharmaceuticals by 842.9% in the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after buying an additional 531 shares during the period. KBC Group NV grew its holdings in ANI Pharmaceuticals by 89.2% in the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock worth $70,000 after acquiring an additional 600 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of ANI Pharmaceuticals in the fourth quarter valued at about $166,000. HighTower Advisors LLC purchased a new position in shares of ANI Pharmaceuticals in the third quarter valued at about $222,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of ANI Pharmaceuticals by 10.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock valued at $246,000 after acquiring an additional 412 shares during the last quarter. Institutional investors own 76.05% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

ANIP has been the topic of a number of research analyst reports. HC Wainwright restated a "buy" rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, March 17th. StockNews.com downgraded ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Tuesday, April 8th. Jefferies Financial Group started coverage on shares of ANI Pharmaceuticals in a report on Friday, March 14th. They issued a "buy" rating and a $80.00 price target on the stock. Guggenheim reaffirmed a "buy" rating and set a $86.00 price objective on shares of ANI Pharmaceuticals in a research report on Friday. Finally, JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an "overweight" rating and a $85.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $79.75.

Insider Activity

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the firm's stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $68.96, for a total transaction of $27,584.00. Following the sale, the vice president now directly owns 80,145 shares of the company's stock, valued at $5,526,799.20. This trade represents a 0.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Krista Davis sold 1,000 shares of the company's stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $60.20, for a total value of $60,200.00. Following the completion of the transaction, the senior vice president now directly owns 68,624 shares of the company's stock, valued at approximately $4,131,164.80. This trade represents a 1.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,200 shares of company stock valued at $197,792 over the last ninety days. 12.70% of the stock is currently owned by corporate insiders.

ANI Pharmaceuticals Stock Up 1.2 %

ANIP stock traded up $0.83 during midday trading on Tuesday, hitting $69.55. The company's stock had a trading volume of 189,818 shares, compared to its average volume of 268,605. The company has a market cap of $1.51 billion, a PE ratio of -126.45 and a beta of 0.49. The firm's 50-day moving average is $62.52 and its 200-day moving average is $59.15. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $70.00. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.